Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Understanding IGF-1: Jefferson Researcher Sees Drug Potential in Targeting Enzyme

21.09.2005


He has labored for years over trying to understand and detail the behavior of insulin-like growth factor-1 (IGF-1) receptor, a protein which plays an important role in tumor growth. Several years ago he and his co-workers discovered that normal cells lacking the IGF-1 receptor gene could not be made to turn cancerous. He found that when they “knocked out” IGF-1 receptors in cancer cells, the cells self-destructed, meaning the IGF-1 receptor was somehow necessary for tumor cell growth. Companies are interested in targeting the IGF-1 receptor with the idea of killing cancer cells, he says.



According to Dr. Baserga, who is professor of microbiology and immunology at Jefferson Medical College of Thomas Jefferson University in Philadelphia and acting director of Jefferson’s Kimmel Cancer Center, in the past few years, scientists have learned that the IGF-1 receptor is also a key growth factor that regulates cell and body size. Deleting the genes for the IGF-1 receptor and its docking protein IRS-1 result in mouse and fly embryos that are only 50 percent of normal size.

“This tells you in essence that the IGF-1 receptor and its docking protein control 50 percent of body size in a non-redundant way,” he says. “This was an important finding because it established the role of IGF-1 receptor and IRS-1 in controlling body size.”
Reporting August 19, 2005 in the Journal of Biological Chemistry, Dr. Baserga and his co-workers provide one possible molecular explanation for how this occurs.



They found that when IRS-1 is activated with the IGF-1 receptor, ß-catenin, a protein important in colon and breast cancer is turned on. “We’re the first ones to discover that IRS-1 goes to the cell nucleus, where it binds a protein, ß-catenin, in the nucleus that regulates RNA polymerase 1, the enzyme that controls cell size,” he explains.

He doesn’t think that IRS-1 is the exclusive activator, but rather, one of several. “It makes sense,” he says. “When you knock out the IRS-1 gene, you get flies that are 50 percent in size, so there are other ways to make cells proliferate. Cells without the IGF-1 receptor can grow.”

Several years ago, Dr. Baserga, who pioneered much of the understanding of the basic behavior of the IGF-1 receptor, and his co-workers used knockouts – specially bred mice lacking a particular gene – to develop a cell line without IGF-1 receptors. Normal cells grew, but would not turn cancerous when placed in rodent cells with added cancer-causing genes.

The finding suggested that if cells that lacked IGF-1 receptor could not be turned cancerous, perhaps cancerous cells with IGF-1 could be reversed. “If this is true in humans, then this is a rational target,” he says. Studies by companies in the last few years have found that antibodies and various small molecules made to the IGF-1 receptor kill cancer cells without toxicity, he notes.

“The general idea is that if you find something that knocks out the IGF-1 receptor, you will kill the cancer cells and have only a modest effect on normal cells – at least using cells in culture and in mice,” he says. Several years ago, for example, Dr. Baserga and his group used antisense therapy to target the IGF-1 receptor, which killed cancer cells in mice but didn’t work as well in people. However, clinical trials are just beginning, he says, and he is still hopeful that other approaches will work in humans.

In the meantime, pharmaceutical companies continue to pursue potential drugs and small molecules that target the IGF-1 receptor, and still seek Dr. Baserga’s help.

Steve Benowitz | EurekAlert!
Further information:
http://www.jefferson.edu

More articles from Life Sciences:

nachricht Cryo-electron microscopy achieves unprecedented resolution using new computational methods
24.03.2017 | DOE/Lawrence Berkeley National Laboratory

nachricht How cheetahs stay fit and healthy
24.03.2017 | Forschungsverbund Berlin e.V.

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>